NCT04561518

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,500 (estimated)
• Sponsor: Alnylam Pharmaceuticals · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant

Conditions

• Transthyretin-Mediated Amyloidosis
• ATTR Amyloidosis

Timeline

• Start date: 2020-11-23
• Primary completion: 2030-09-01
• Completion: 2030-09-01
• First posted: 2020-09-23
• Last updated: 2026-03-31

Locations

40 sites across 12 countries: United States, Brazil, Bulgaria, Denmark, France, Germany, Israel, Italy, Netherlands, Portugal, Spain, Taiwan